5 active not recruiting, 4 not yet recruiting, 3 completed, 3 recruiting. 3 Phase 3, 3 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 4 | 3 | Recruiting 2, Completed 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow abrysvo: new trials by email Literature Review of abrysvo trials Research Report on abrysvo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Severe Pediatric Respiratory Syncytial Virus Infections Occurring in the Era of Antiviral Prophylaxis Prior exposure to prophylactic treatment with Abrysvo or nirsevimab/clesrovimab, Non-exposure to prior prophylactic treatment - Children <24 Months Hospitalized for RSV-related Lower Respiratory Tract Infection | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 300 | 2026-11-15 | 2026-10-26 | |
| Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset ABRYSVO - Respiratory Syncytial Virus Infections | Not yet recruiting | Pfizer | 1 | 2026-10-15 | 2026-09-24 | |
| Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination Nirsevimab, Abrysvo - RSV Immunization | Phase 3 | Recruiting | Centre Hospitalier Annecy Genevois | 1000 | 2026-05-06 | 2026-05-27 |
| Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women MKK900 60 µg, MKK900 120 µg, ABRYSVO® - Respiratory Syncytial Virus (RSV) | Phase 1 | Not yet recruiting | MAXVAX Biotechnology Limited Liability Company | 120 | 2026-04-01 | 2026-03-25 |
| Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá RSVpreF vaccine (Abrysvo) and Nirsevimab (Beyfortus) or unexposed - Respiratory Syncytial Virus Infections, Severe Acute Respiratory Infection | Active not recruiting | Bogotá District Health Secretariat | 1097 | 2026-01-01 | 2026-08-06 | |
| Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants ABRYSVO - Respiratory Syncytial Virus (RSV) | Active not recruiting | Pfizer | 1 | 2025-12-01 | 2026-06-10 | |
| Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy Tdap Vaccine Administration, RSV Vaccine, Saline (as a placebo) - RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination | Phase 4 | Recruiting | Canadian Immunization Research Network | 60 | 2025-10-16 | 2026-10-22 |
| Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination. Abrysvo, Nirsevimab - RSV Immunization | Phase 3 | Not yet recruiting | PENTA Foundation | 1500 | 2025-09-01 | 2025-06-27 |
| STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON) ABRYSVO - Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus | Active not recruiting | Pfizer | 1 | 2025-08-11 | 2025-11-19 | |
| SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER RSVpreF vaccine - Respiratory Syncytial Virus Infection | Active not recruiting | Pfizer | 1100 | 2025-05-27 | 2026-10-29 | |
| A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE - Respiratory Syncytial Virus (RSV) | Phase 3 | Completed | Pfizer | 526 | 2025-04-04 | 2025-11-06 |
| SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS RSVpreF vaccine - Respiratory Tract Infection | Completed | Pfizer | 497 | 2024-10-01 | 2026-04-09 | |
| The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products Abrysvo, Beyfortus - Respiratory Syncytial Virus Infection | Phase 4 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 181 | 2024-09-19 | 2026-05-11 |
| Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy ABRYSVO - Respiratory Syncytial Virus, Respiratory Tract Diseases | Active not recruiting | Pfizer | 1 | 2024-08-26 | 2026-05-15 | |
| Vaccine Responses in Patients With B Cell Malignancies AREXVY, ABRYSVO, PREVNAR 20, PNEUMOVAX 23 - Lymphoma | Phase 4 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 350 | 2022-09-14 | 2026-08-04 |
Respiratory Syncytial Virus Infections (5) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Bronchiolitis, Viral (1) · Diphtheria (1) · Lymphoma (1)
Pfizer (7) · Assistance Publique - Hôpitaux de Paris (1) · Bogotá District Health Secretariat (1) · Canadian Immunization Research Network (1) · Centre Hospitalier Annecy Genevois (1) · MAXVAX Biotechnology Limited Liability Company (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · PENTA Foundation (1)
United States (4) · Australia (2) · France (2) · Japan (2) · Argentina (1) · Canada (1) · Colombia (1) · Puerto Rico (1)
Adrian U Wiestner, M.D. (1) · Bahaa Abu-Raya, M.D., PhD (1) · Pierre Frange (1)
2025 (2), 5UM1AI148684-04 (1)